Giloralimab

DB18862InvestigationalProtein Based Therapies

Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV...

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 5
Curator reviewed
Also known as: Agonistic anti-cd40 monoclonal antibody abbv-927 · Anti-cd40 agonist monoclonal antibody abbv-927 · Immunoglobulin g1, anti-(human cd40 antigen) (human-mus musculus monoclonal pr-1614645 .gamma.1-chain), disulfide with human-mus musculus monoclonal pr-1614645 .kappa.-chain, dimer
Code names: ABBV-927 · PR-1614645

Resolves to

Compound

UNIIW6C58X3BFHCAS2226292-20-0

Targets

P25942CD40

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Giloralimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account